Intratumoral heterogeneity and clonal evolution in blood malignancies and solid tumors
PDF | HTML | How to cite
Metrics: PDF 917 views | HTML 1705 views | ?
Ignacio Varela1, Pablo Menendez2,3,4 and Alejandra Sanjuan-Pla5
1 Instituto de Biomedicina y Biotecnología de Cantabria, Universidad de Cantabria-CSIC, Santander, Spain
2 Department of Biomedicine, Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, Barcelona, Spain
3 Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain
4 Red de Investigación Biomédica en Red de Cáncer (CIBERONC), ISCIII, Barcelona, Spain
5 Hematology Research Group, IIS La Fe, Valencia, Spain
Alejandra Sanjuan-Pla, email:
Keywords: cancer genomics, intratumoral heterogeneity, tumor evolution, oncology practice, bioinformatics
Received: June 16, 2017 Accepted: July 25, 2017 Published: August 16, 2017
This meeting held at the University of Barcelona in March 2017, brought together scientists and clinicians worldwide to discuss current and future clinico-biological implications of intratumoral heterogeneity (ITH) and subclonal evolution in cancer diagnosis, patient stratification, and treatment resistance in diagnosis, treatment and follow-up. There was consensus that both longitudinal and tumor multi-region studies in matched samples are needed to better understand the dynamics of ITH. The contribution of the epigenome and microenvironment to ITH and subclone evolution remains understudied. It was recommended to combine computational, pathology and imaging tools to study the role of the microenvironment in subclone selection/evolution.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.